Bayer, J&J kick off 2 more trials of rivaroxaban

03/12/2013 | PharmaTimes (U.K.)

Bayer and Johnson & Johnson are initiating two late-stage trials of the anticoagulant rivaroxaban after failing to get expanded FDA approval for the prevention of cardiovascular events in patients with acute coronary syndrome. One trial will involve individuals with chronic heart failure and significant coronary artery disease. The other will include patients with nonvalvular atrial fibrillation.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT